Jnj-17299425
Traumatic Brain Injury
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
93 Active assets in the Traumatic Brain Injury cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
MELATONIN Children's National Research Institute | Phase 4 | BBB |
Valproic Acid Northwestern University | Phase 4 | BBB |
PROPRANOLOL Tanta University | Phase 4 | BBB |
NEPENTHE Henry M. Jackson Foundation for the Advancement of Military Medicine | Phase 4 | BB |
N-Acetyl-L-Cysteine HonorHealth Research Institute | Phase 2 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →